Valneva reports wider loss despite revenue growth

Valneva reported a FY2025 net loss of EUR 115.20m (worsening from prior year) and adjusted EBITDA of negative EUR 59.40m, driven partly by the absence of a 2024 one-off gain. Revenue rose modestly on higher sales of proprietary vaccines (Japanese encephalitis and chikungunya) but gross margins were hit by higher manufacturing costs, batch failures and inventory write-offs; R&D spend increased for the Shigella program and post-marketing chikungunya obligations. For 2026 the company reiterated revenue guidance of EUR 155–170m (product sales EUR 145–160m) and expects operating cash burn to decline further, with key clinical trial readouts anticipated during the year.

Analysis

Valneva’s problems are downstream executional rather than demand-driven, which creates asymmetric outcomes: manufacturing quality issues and batch failures can compress near-term margins and trigger regulatory scrutiny or contract penalties, while successful remediation is largely binary and confined to a few quarters. That elevates counterparty and CDMO dynamics — outsourced manufacturers and larger vaccine players with redundant capacity (and balance sheets) stand to capture incremental contracts and pricing power if Valneva cannot stabilize production.

The clearest catalysts are clinical readouts (Shigella, post-marketing chikungunya obligations) and the cadence of manufacturing remediation; expect meaningful share-price moves around each readout (positive → multi-bagger rerate vs negative → rapid funding/insolvency repricing). Tail risks live in the financing runway and regulatory actions: if operating cash burn does not decline as guided, equity dilution or fire-sale M&A within 6–12 months becomes the dominant downside path.

A contrarian thesis is plausible: the headline loss was driven by a non-recurring accounting item plus discrete batch write-offs, while recurring product sales grew; if readouts are positive and manufacturing fixes are demonstrably validated in Q2–Q3 2026, upside is concentrated because the enterprise value today underweights future commercial sales and acquisition optionality. That makes option-based, event-driven structures more attractive than outright directional exposure until execution risk narrows.

Key Decisions for Investors

• Short VALN equity (size 0.5–1% NAV) over 3–12 months: thesis is continued margin pressure, potential for further batch-related write-offs and dilutive capital raises. Target -30–40% downside; stop at +20% to limit squeeze risk.
• Buy VALN 18–24 month call spreads (e.g., Jan 2027 LEAP call spread) sized 0.5–1% NAV, funded by selling nearer-term calls: asymmetric payoff to capture positive Shigella readout or remediation evidence while limiting premium. Reward scenario: >3x if readout positive and manufacture validated; loss limited to premium paid if negative.
• Event-driven long call spread into each clinical readout (6–9 months window): purchase a 6–12 month call spread 30–50% OTM with a defined max loss (premium) sized small (0.25–0.5% NAV). If readout is positive, take profits quickly (target +100–300%); if negative, close below 50% of premium.
• Pair trade: Long CDMO/external manufacturing beneficiaries (e.g., CTLT or LZAGY) vs short VALN (equal notional, 3–12 months). Rationale: capture reallocation of production and pricing to higher-quality manufacturers; expect relative outperformance of 10–30% if Valneva remediation fails.